Breast Care最新文献

{"title":"Prognostic Impact of Immunophenotypic Variation in Subcapsular Sinus Endothelium of Sentinel Lymph Nodes in Invasive Breast Carcinoma.","authors":"Jonas Derben, Markus Oeruem, Carolin Blasberg, Akira Hattesohl, Paul Jank, Matthias Kalder, Carsten Denkert, Christina C Westhoff","doi":"10.1159/000543600","DOIUrl":"10.1159/000543600","url":null,"abstract":"<p><strong>Introduction: </strong>Several studies demonstrated the de novo formation of lymphatic vessels in tumor-draining lymph nodes (LNs), partly preceding lymphatic metastases. This \"lymphovascular niche\" supposedly facilitates survival of metastatic tumor cells. This study aims at evaluating the previously observed immunophenotypic variations of subcapsular endothelial cells (SECs) in a larger cohort by software-assisted image analysis.</p><p><strong>Methods: </strong>Suitable cases with sentinel-LN (SLN) of invasive breast cancer were identified in the Institute of Pathology, corresponding data were extracted. LN of 231 patients were stained for HE, D2-40, CD31, and Prox1. QuPath software was used for assessing the immunohistochemical stained area of endothelial cells of the subcapsular sinus. The Cutoff Finder web application was used for identification of the best cutoff for continuous parameters according to overall survival (OS). Collected data were statistically evaluated for available data.</p><p><strong>Results: </strong>A larger area of CD31-positive SEC was significantly associated with worse OS (<i>p</i> = 0.001), as was a higher proportion of D2-40-stained subcapsular sinus (<i>p</i> = 0.045). Larger area of D2-40-/CD31-/Prox1-positive SEC and higher proportion of D2-40 stained subcapsular sinus were independent marker for worse OS in multivariate analysis in the whole cohort, for D2-40- and CD31-positive SECs as well as higher proportion of D2-40-stained sinus including nodal-negative status, respectively.</p><p><strong>Conclusion: </strong>QuPath-assisted evaluation of immunophenotypic variation in subcapsular sinus endothelium in SLN essentially confirmed and extended our previous findings. Larger positive area of D2-40- and CD31-positive SECs emerged as a strong independent negative prognostic factor, even before evident nodal metastasis. The potential function of alterations in D2-40-/CD31-expression in SECs has yet to be elucidated.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"20 2","pages":"75-87"},"PeriodicalIF":2.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12005704/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143965440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeted Axillary Dissection Using Surgical Marker Navigation after Neoadjuvant Systemic Treatment in Breast Cancer Patients: A Single-Center Experience.","authors":"Daniel Egle, Christine Brunner, Magdalena Ritter, Verena Wieser, Katharina Knoll, Birgit Amort, Afshin Soleiman, Heidelinde Fiegl, Christian Marth, Carmen Albertini, Rupert Bartsch","doi":"10.1159/000541704","DOIUrl":"10.1159/000541704","url":null,"abstract":"<p><strong>Background: </strong>In early-stage breast cancer with initially positive axillary lymph nodes, reliable assessment of the involvement of the axilla is important because of the prognostic importance of lymph node metastases. After neoadjuvant chemotherapy (NACT), targeted axillary dissection (TAD), including sentinel lymph node biopsy and primarily involved lymph nodes, is currently regarded as the standard of care. The target lymph node must be marked using a clip/marker and later localized using a reliable guidance technique to identify the node, to avoid the indication of axillary lymph node dissection.</p><p><strong>Methods: </strong>The present study aimed to evaluate retrospective data collected from April 25, 2022, until March 30, 2023, on a consecutive series of patients, to determine the efficacy and safety of using the Sirius Pintuition GPSDetect^™ surgical marker navigation system.</p><p><strong>Results: </strong>This consecutive case series shows that identification of the target node with surgical marker navigation is feasible and safe, with a 100% identification rate at surgery, in a population of 20 patients with histologically verified axillary lymph node involvement before NACT.</p><p><strong>Conclusion: </strong>Magnetically guided localization systems may therefore be a valid alternative to ultrasound-guided wire placement. The data highlight the practicality of the magnetically guided approach, which potentially contributes to a reduction in treatment-related morbidity by avoiding unnecessary axillary lymph node dissection.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"20 2","pages":"57-65"},"PeriodicalIF":2.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12005687/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143967676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Large-Scale Population Screening for <i>BRCA1</i> and <i>BRCA2</i> Ashkenazi Founder Mutations: Perspectives of Professionals Providing Oncogenetic Consultations.","authors":"Yael Furman, Yoel Gofin, Shira Litz Philipsborn, Shulamit Hartmajer, Rivka Sukenik-Halevy","doi":"10.1159/000543678","DOIUrl":"10.1159/000543678","url":null,"abstract":"<p><strong>Introduction: </strong>In March 2020, a nationwide population carrier screening for <i>BRCA1/2</i> pathogenic variants among Ashkenazi Jewish women was initiated in Israel. We aimed to assess views regarding the program among professionals who provide oncogenetic counseling for detected carriers.</p><p><strong>Methods: </strong>An online survey was distributed to clinical geneticists and genetic counselors.</p><p><strong>Results: </strong>The participants' impression was that most carriers did not comprehend the implications of a positive result when deciding to take the test. Some carriers, in retrospect, regretted taking it. Some had a known mutation carrier in the family, and some had a family history that justified a broader test (and so should not have been tested through the screening program). Eight survey participants (29%) reported they were initially against the screening program, but half of them are currently in favor of it. Most participants are unsatisfied with the way the screening is conducted and suggested various improvements. Emotional distress of carriers, as assessed by participants, was higher for those detected by the screening program, compared to those tested after oncogenetic counseling. No association was found between the age, profession, and prior experience of participants and their responses.</p><p><strong>Conclusions: </strong>While the general attitude toward the screening program is positive, most professionals feel the need to improve the current screening program by defining exclusion criteria, providing comprehensive pretest information and adding other BRCA1/2 founder mutations, as well as expanding the screening to include ethnicities other than Ashkenazi Jews.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"20 2","pages":"111-117"},"PeriodicalIF":2.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12005690/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143976552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigation of Risk Factors and Development and Validation of a Nomogram for Predicting Overall Survival in Breast-Invasive Lobular Carcinoma.","authors":"Mingjie Yuan, Ying Yin, Zhaoxin Chu, Jianming Yan","doi":"10.1159/000543865","DOIUrl":"10.1159/000543865","url":null,"abstract":"<p><strong>Objective: </strong>Invasive lobular carcinoma (ILC) of the breast is a common pathological subtype of breast cancer, ranks second in terms of incidence rate following invasive ductal carcinoma. The aims of this study were to construct a nomogram for predicting overall survival (OS) in patients with ILC and to identify risk factors that affect their survival prognosis.</p><p><strong>Methods: </strong>The patients diagnosed with ILC between 2010 and 2015 were extracted from Surveillance, Epidemiology, and End Results (SEER) database. They were randomly split into a training set with 18,365 samples for model training and parameter tuning and a validation set with 7,872 samples for independent accuracy verification. The independent risk factors were screened by lasso regression and multivariable Cox regression. A nomogram was constructed for the 3-year, 5-year, and 10-year OS rates based on these independent risk factors. Model efficiency was assessed through Harrell's concordance index (C-index), calibration curves, receiver operating characteristic curves, and decision curve analysis (DCA).</p><p><strong>Results: </strong>A total of 26,237 patients diagnosed with ILC were included. The following factors were identified as independent risk factors associated with OS: age, marital status, grade, estrogen receptor, progesterone receptor, surgery, radiation therapy, tumor size (T), lymph node (N), and metastasis (M) stages. The C-index was 0.795 in the training set, while in the validation set it was 0.791. The corresponding areas under the curve for 3-year, 5-year, and 10-year OS were 0.837, 0.828, and 0.791 in the training set and 0.832, 0.826, and 0.781 in the validation set, respectively. The calibration curve of the nomogram showed good consistency, and the DCA curves also suggested that it can provide valuable guidance for clinical decision-making.</p><p><strong>Conclusions: </strong>The established nomogram predicting 3-year, 5-year, and 10-year OS for patients with ILC showed a good performance and it can help clinicians make more favorable clinical decisions.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"20 2","pages":"118-131"},"PeriodicalIF":2.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12005703/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143976989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of Lifestyle and Genetic Risk Factors in Urban Women in China Who Had Malignant or Suspected Malignant Breast Nodules Identified via Breast Cancer Screening.","authors":"Jun-Luan Mo, Lin Lei, Xi Li, Hong-Hao Zhou, Li-Jun Zhang, Wen-Xu Hong, Ji-Ye Yin","doi":"10.1159/000545279","DOIUrl":"https://doi.org/10.1159/000545279","url":null,"abstract":"<p><strong>Objective: </strong>Breast cancer seriously endangers women's health. It is very important to analyze the lifestyle and genetic risk factors for people with malignant or suspected malignant nodules in breast cancer screening for the prevention of breast cancer.</p><p><strong>Methods: </strong>A total of 3,142 urban female residents in southern China completed a clinical screening for breast cancer. The participants completed questionnaires on living environmental factors and underwent clinical imaging examinations and genetic testing of 73 SNP loci. According to the BI-RADS classification results, the population was divided into positive and negative groups. Key factors were identified through intergroup differences and association analysis. Lifestyle models, SNP models, and lifestyle + PRS models were constructed. ROC curves and nomograms were used to evaluate the classification effect of the model.</p><p><strong>Results: </strong>There were 10 lifestyle factors that were significantly different between the groups, 4 of which were significantly associated with positive breast imaging results (<i>p</i> < 0.05), including age (OR = 0.972, 95% CI: 0.957-0.988), duration of breastfeeding (0.982, 0.970-0.994), history of benign breast disease (1.838, 1.299-2.599), and high-fat diet (1.507, 1.166-1.947). There were 5 significant SNPs, including <i>BRCA2</i>-rs1799955, <i>TLR1</i>-rs4833095, <i>ZNF365</i>-rs10822013, <i>SLC4A7</i>-rs4973768, and <i>BRCA2</i>-rs144848. The AUC values for the lifestyle, SNP, and lifestyle + PRS models were 0.625, 0.598, and 0.633, respectively. The C index of the lifestyle + PRS model was 0.633.</p><p><strong>Conclusion: </strong>Advocating breastfeeding, reducing the intake of high-fat diets, and protecting breast health may help lower the risk of positive results in breast screenings. The combination of lifestyle factors and genetic factors can enhance the predictive power of the model.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":"1-13"},"PeriodicalIF":2.0,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12052347/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143960513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of Life in Patients Pre- and Post-Breast Reduction Surgery in a South African Population: A Single-Centred Patient-Based Study.","authors":"Nokubonga Khwela, Anil Madaree, Nivana Mohan, Lelika Lazarus","doi":"10.1159/000543306","DOIUrl":"https://doi.org/10.1159/000543306","url":null,"abstract":"<p><strong>Introduction: </strong>Breast hypertrophy is the abnormal enlargement of breast tissue resulting in extremely large breasts and is a regular condition among women worldwide. It can affect different aspects of their life, including their psycho-social, sexual, emotional, and physical well-being. This study aimed to assess the quality of life in individuals with breast hypertrophy both before and after undergoing breast reduction surgery.</p><p><strong>Methods: </strong>Two sets of questionnaires (preoperative and post-operative) were formulated and distributed to 18 patients (median age of 31, age range: 18-48 years) undergoing breast reduction surgery. Patients were also provided with an informed consent form.</p><p><strong>Results: </strong>Preoperatively, most patients expressed different levels of dissatisfaction with themselves across all categories. However, post-operatively, significant levels (<i>p</i> < 0.05, <i>p</i> < 0.001) of satisfaction were demonstrated by patients, as 100% of them reported a reduction in back pain and heaviness of breasts, and 100% reported improvement in their self-confidence. Also, 94% and 65% reported improvement in their social interaction and sexual life, respectively, while 83% and 61% of patients reported satisfaction in carrying their grocery shopping bags and their engagement in regular exercise programs, respectively.</p><p><strong>Conclusion: </strong>The study illustrates that breast reduction surgery had a positive effect on the quality of life of patients as a significant proportion of them reported improvement and satisfaction across all categories following the procedure.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":"1-11"},"PeriodicalIF":2.0,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12052368/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143989653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Banana Supplementation for Breast Cancer Surgery Patients: A Two-Center Experience.","authors":"Yang Jiang, Xin Ma, Lei Niu, Yaoyao Jiang","doi":"10.1159/000545174","DOIUrl":"https://doi.org/10.1159/000545174","url":null,"abstract":"<p><strong>Introduction: </strong>Patients frequently encounter both physical and mental challenges after undergoing surgery for breast cancer, leading to a negative impact on their general well-being. Our objective was to investigate the beneficial effects of dietary supplementation with bananas on patients after breast cancer surgery.</p><p><strong>Methods: </strong>Among breast cancer patients who had undergone breast surgery, the banana group (<i>n</i> = 77) consumed an additional banana daily alongside their regular diet, while the non-banana group (<i>n</i> = 77) did not. Negative emotions, sleep quality, sexual health, complication rates, length of hospital stay, and quality of life were assessed.</p><p><strong>Results: </strong>Compared to the non-banana group, patients in the banana group exhibited lower levels of depression and anxiety, better sleep quality, more satisfactory sexual quality of life, and a higher overall quality of life postoperatively. Nonetheless, the complication rates and length of hospital stay did not show any notable variances between the 2 groups.</p><p><strong>Conclusion: </strong>This study highlights the novel finding that simple dietary supplementation with bananas significantly enhances mental well-being and overall quality of life in breast cancer patients following surgery, despite no notable impact on physical recovery metrics.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":"1-10"},"PeriodicalIF":2.0,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12052346/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143974159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Do We Need Anthracyclines for Elderly Patients with Triple-Negative Breast Cancer?","authors":"Stefan Lukac, Visnja Fink, Thomas W P Friedl, Franziska Mergel, Kerstin Pfister, Henning Schäffler, Davut Dayan, Sabine Heublein, Brigitte Rack, Wolfgang Janni, Elena Leinert","doi":"10.1159/000544906","DOIUrl":"https://doi.org/10.1159/000544906","url":null,"abstract":"<p><strong>Objectives: </strong>Triple-negative breast cancer (TNBC) requires chemotherapy-based systemic treatment which is usually anthracycline-based (AB). The cardiotoxicity of AB regimens is especially relevant in the elderly population. Therefore, we retrospectively compared survival and toxicity between elderly patients with early TNBC receiving AB or anthracycline-free (AF) adjuvant chemotherapy to evaluate whether elderly patients with TNBC could be spared anthracycline-related toxicity without compromising survival.</p><p><strong>Methods: </strong>The study population comprised 221 women with TNBC older than 65 years from the SUCCESS A and SUCCESS C studies, who underwent primary surgery and received either AB (3x fluorouracil-epirubicin-cyclophosphamide followed by 3x docetaxel) or AF (6x docetaxel-cyclophosphamide) adjuvant chemotherapy according to a standardized protocol. The two groups were compared regarding clinicopathological parameters (pT, pN, grading, histological subtype, type of surgery, adjuvant radiotherapy) and side effects using chi-square tests, and regarding survival (overall survival, invasive disease-free survival, breast-cancer specific survival, distant disease-free survival) using log-rank tests and Cox regressions.</p><p><strong>Results: </strong>There was no significant difference between the two groups regarding any of the clinicopathological parameters, and no significant difference was observed in survival parameters. However, elderly patients with the AB regime had significantly more often grade 3 or 4 adverse events (75.2% vs. 50.6%, <i>p</i> < 0.001) during adjuvant chemotherapy than patients with the AF regimen.</p><p><strong>Conclusion: </strong>In our retrospective analysis of SUCCESS A and C trial, the use of AF chemotherapy in elderly patients with TNBC was associated with similar survival rates but less toxicity compared to AB chemotherapy. Further randomized controlled trials with AF regimen focusing on elderly patients with TNBC are necessary to confirm our results.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":"1-9"},"PeriodicalIF":2.0,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12052345/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143983089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2025.","authors":"Tjoung-Won Park-Simon, Volkmar Müller, Ute-Susann Albert, Maggie Banys-Paluchowski, Rupert Bartsch, Ingo Bauerfeind, Vesna Bjelic-Radisic, Jens-Uwe Blohmer, Wilfried Budach, Peter Dall, Nina Ditsch, Eva M Fallenberg, Peter A Fasching, Tanja Fehm, Michael Friedrich, Bernd Gerber, Oleg Gluz, Nadia Harbeck, Andreas Daniel Hartkopf, Jörg Heil, Juliane Hörner-Rieber, Jens Huober, Hans-Heinrich Kreipe, David Krug, Thorsten Kühn, Sherko Kümmel, Sibylle Loibl, Diana Lüftner, Michael Patrick Lux, Nicolai Maass, Christoph Mundhenke, Toralf Reimer, Mattea Reinisch, Kerstin Rhiem, Achim Rody, Marcus Schmidt, Andreas Schneeweiss, Florian Schütz, Hans-Peter Sinn, Christine Solbach, Erich-Franz Solomayer, Elmar Stickeler, Christoph Thomssen, Michael Untch, Marion Tina van Mackelenbergh, Isabell Witzel, Achim Wöckel, Rachel Wuerstlein, Wolfgang Janni, Marc Thill","doi":"10.1159/000545019","DOIUrl":"https://doi.org/10.1159/000545019","url":null,"abstract":"<p><p>The Breast Committee of the Arbeitsgemeinschaft Gynäkologische Onkologie (German Gynecological Oncology Group, AGO) presents the 2025 update of the evidence-based recommendations for the diagnosis and treatment of patients with early breast cancer.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":"1-19"},"PeriodicalIF":2.0,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11996201/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143983071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2025.","authors":"Marc Thill, Wolfgang Janni, Ute-Susann Albert, Maggie Banys-Paluchowski, Rupert Bartsch, Ingo Bauerfeind, Vesna Bjelic-Radisic, Jens Blohmer, Wilfried Budach, Peter Dall, Nina Ditsch, Eva Maria Fallenberg, Peter A Fasching, Tanja Fehm, Michael Friedrich, Bernd Gerber, Oleg Gluz, Nadia Harbeck, Andreas Hartkopf, Jörg Heil, Juliane Hörner-Rieber, Jens Huober, Hans-Heinrich Kreipe, David Krug, Thorsten Kühn, Sherko Kümmel, Sibylle Loibl, Diana Lüftner, Michael Patrick Lux, Nicolai Maass, Christoph Mundhenke, Mattea Reinisch, Toralf Reimer, Kerstin Rhiem, Achim Rody, Marcus Schmidt, Andreas Schneeweiss, Florian Schütz, Hans-Peter Sinn, Christine Solbach, Erich-Franz Solomayer, Elmar Stickeler, Christoph Thomssen, Michael Untch, Marion van Mackelenbergh, Isabell Witzel, Achim Wöckel, Rachel Würstlein, Volkmar Müller, Tjoung-Won Park-Simon","doi":"10.1159/000545018","DOIUrl":"https://doi.org/10.1159/000545018","url":null,"abstract":"<p><p>The Breast Committee of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO; German Gynecological Oncology Group) presents the 2025 update of the evidence-based recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer (mBC).</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":"1-12"},"PeriodicalIF":2.0,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12052354/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143970087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}